Lakewood-Amedex Biotherap... (LABT)
NasdaqCM: LABT
· Prix en temps réel · USD
2.27
-0.06 (-2.58%)
À la clôture : Aug 14, 2026, 3:59 PM
2.17
-4.32%
Après-Bourse: 7:59 PM
Description de l’entreprise
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Lakewood-Amedex Biotherapeutics Inc.
| Pays | United States |
| Date d’introduction | 23 avr. 2026 |
| Industrie | Biotechnology |
| Secteur | Healthcare |
| Employés | 5 |
| CEO | Dr. Kelvin Cooper Ph.D. |
Coordonnées
Adresse : 8031 Cooper Creek Blvd. University Park, FL United States | |
| Site web | https://lakewoodamedex.com |
Données boursières
| Symbole boursier | LABT |
| Marché | NasdaqCM |
| Exercice fiscal | Jan '25 - Dec '25 |
| Devise de présentation | USD |
| Code CIK | 0002079272 |
| Numéro CUSIP | n/a |
| Numéro ISIN | n/a |
| Identifiant employeur | n/a |
| Code SIC | n/a |
Dirigeants clés
| Nom | Position |
|---|---|
| Dr. Kelvin Cooper Ph.D. | CEO, SVP of Research & Development and Director |
| Mr. Peter F. Ceccacci | CFO & VP of Administration |
| Dr. Thomas Balzer M.D., Ph.D. | Chief Medical Officer & SVP of Clinical Development |
| Ms. Tara Endress | Project Manager & Accounting Manager |
| Daniel Kontoh-Boateng | Investor Relations |